top of page
  • EVI

International partnership to advance the development of a new vaccine against Shigella and ETEC

Horizon2020 award to consortium will support the testing of an innovative live attenuated vaccine in phase I clinical trials in Europe and Bangladesh.

Under coordination by EVI, the SHIGETECVAX consortium, made up of partners including EVI, Eveliqure, icddr,b, University of Gothenburg, and PATH, will be advancing a radically new approach for a vaccine against Shigella and ETEC, developed by Eveliqure Biotechnologies.

To read the full EVI news release, please click this link:

To read the full EVQ news release, please click this link:


bottom of page